Tandem Diabetes (TNDM) is gaining from continued product innovations. Yet, rising costs put pressure on margins. The stock carries a Zacks Rank #3 (Hold).Tandem Diabetes is driving transformative innovation to help reduce the burden and create new possibilities for people living with diabetes. During the second quarter, its flagship t:slim X2 insulin pump software became compatible with Dexcom G7. It was already compatible with Dexcom G6 Continuous Glucose Monitoring (CGM) systems. Following this developmen ...